Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVAC NASDAQ:JBIO NASDAQ:MGNX NASDAQ:PURR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/AJBIOJade Biosciences$21.34+0.2%$20.68$6.67▼$28.00$1.05B1.431.29 million shs1.22 million shsMGNXMacroGenics$4.29-4.7%$4.20$1.29▼$5.08$286.03M1.181.31 million shs1.28 million shsPURRHyperliquid Strategies$7.36+2.8%$8.24$3.01▼$11.62$1.03B1.6612.86 million shs9.90 million shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac0.00%0.00%0.00%0.00%-14.65%JBIOJade Biosciences+0.19%-4.94%+39.11%+10.80%+137.11%MGNXMacroGenics-4.67%-9.68%+8.33%+21.88%+171.52%PURRHyperliquid Strategies+2.79%-10.02%-15.40%+13.06%+735,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/AJBIOJade Biosciences$21.34+0.2%$20.68$6.67▼$28.00$1.05B1.431.29 million shs1.22 million shsMGNXMacroGenics$4.29-4.7%$4.20$1.29▼$5.08$286.03M1.181.31 million shs1.28 million shsPURRHyperliquid Strategies$7.36+2.8%$8.24$3.01▼$11.62$1.03B1.6612.86 million shs9.90 million shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac0.00%0.00%0.00%0.00%-14.65%JBIOJade Biosciences+0.19%-4.94%+39.11%+10.80%+137.11%MGNXMacroGenics-4.67%-9.68%+8.33%+21.88%+171.52%PURRHyperliquid Strategies+2.79%-10.02%-15.40%+13.06%+735,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVACCureVac 1.00SellN/AN/AJBIOJade Biosciences 2.90Moderate Buy$51.57141.67% UpsideMGNXMacroGenics 2.29Hold$5.5028.21% UpsidePURRHyperliquid Strategies 2.50Moderate Buy$12.7272.78% UpsideCurrent Analyst Ratings BreakdownLatest MGNX, PURR, JBIO, and CVAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026PURRHyperliquid Strategies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $18.406/16/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/15/2026JBIOJade Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/15/2026JBIOJade Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/12/2026PURRHyperliquid Strategies Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.756/3/2026PURRHyperliquid Strategies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)6/2/2026JBIOJade Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$55.006/2/2026JBIOJade Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.006/2/2026JBIOJade Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $45.006/1/2026JBIOJade Biosciences Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVACCureVac$70.74M14.78$0.99 per share4.73$3.36 per share1.39JBIOJade BiosciencesN/AN/AN/AN/A$6.74 per shareN/AMGNXMacroGenics$149.50M1.82N/AN/A$0.88 per share4.88PURRHyperliquid Strategies$1M1,063.15N/AN/A$1.52 per share4.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVACCureVac$175.50M$0.726.47N/AN/A199.92%-23.03%-19.09%N/AJBIOJade Biosciences-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/AMGNXMacroGenics-$74.62M-$1.10N/AN/AN/A-44.79%-147.80%-28.40%8/13/2026 (Estimated)PURRHyperliquid Strategies-$16.01M-$7.37N/AN/AN/AN/A-56.04%-52.22%N/ALatest MGNX, PURR, JBIO, and CVAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026MGNXMacroGenics-$0.57-$0.58-$0.01-$0.58$15.24 million$20.78 million5/7/2026Q1 2026JBIOJade Biosciences-$0.52-$0.57-$0.05-$0.57N/AN/A5/7/2026Q3 2026PURRHyperliquid StrategiesN/A$1.01N/A$1.01N/A$2.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVACCureVacN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/APURRHyperliquid StrategiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVACCureVac0.033.703.69JBIOJade BiosciencesN/A14.2914.29MGNXMacroGenicsN/A1.901.80PURRHyperliquid StrategiesN/A18.2318.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVACCureVac17.26%JBIOJade BiosciencesN/AMGNXMacroGenics96.89%PURRHyperliquid Strategies9.45%Insider OwnershipCompanyInsider OwnershipCVACCureVac2.15%JBIOJade Biosciences23.06%MGNXMacroGenics13.60%PURRHyperliquid Strategies8.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVACCureVac880224.34 million219.52 millionOptionableJBIOJade Biosciences2049.36 million37.98 millionN/AMGNXMacroGenics43063.56 million54.92 millionOptionablePURRHyperliquid StrategiesN/A144.45 million132.20 millionN/AMGNX, PURR, JBIO, and CVAC HeadlinesRecent News About These CompaniesHyperliquid Strategies Inc (PURR) Slides 3.91%: Testing Key Support Levels Amid Bearish Pressure - Dealer GammaJuly 13 at 7:19 PM | donanimhaber.comDHyperliquid Strategies (NASDAQ:PURR) Shares Gap Up - Time to Buy?July 10, 2026 | marketbeat.comDefiance Launches PUR: The First 2X Long PURR ETFJuly 8, 2026 | globenewswire.comTraders Purchase Large Volume of Hyperliquid Strategies Call Options (NASDAQ:PURR)July 8, 2026 | americanbankingnews.comWhy Money Is Leaving Bitcoin for HyperliquidJuly 3, 2026 | aol.comAHyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI IndicesJune 29, 2026 | prnewswire.comHyperliquid Strategies Enhances Executive Compensation and Leadership StructureJune 26, 2026 | tipranks.comPanther Minerals Announces Brokered Private Placement of up to $3,000,000June 16, 2026 | accessnewswire.comAHyperliquid Strategies shares jump as HYPE token strength and late-June index reconstitution fuel buyingJune 16, 2026 | quiverquant.comQHyperliquid Strategies Stock Is Surging Tuesday: What's Driving The Action?June 16, 2026 | benzinga.comWhy Is Hyperliquid Strategies Stock Gaining Monday?June 15, 2026 | benzinga.comPanther Minerals Announces Appointment of Harrison Glancy to Board of DirectorsJune 10, 2026 | accessnewswire.comAHyperliquid Strategies (PURR) Is Down 14.6% After Gamma Squeeze Speculation and Index Inclusion Buzz – What's ChangedJune 7, 2026 | finance.yahoo.comComparing HYPE & PURR: The Most Stock-Like Crypto PlayJune 5, 2026 | seekingalpha.comArthur Hayes: My $100,000 Against Yours That SOL Will Not Outperform The Hottest Coin In The MarketJune 2, 2026 | benzinga.comPURR Stock On Track For Record High After Hyperliquid Flips Dogecoin To Enter Crypto Top 10June 1, 2026 | finance.yahoo.comHyperliquid Is 'Bigger Than Nasdaq,' Says ICE CEO — HYPE Eyes New Record High, While ETFs Top $100MMay 30, 2026 | finance.yahoo.comHyperliquid Strategies (PURR) jumps as Russell Microcap inclusion chatter lifts demandMay 29, 2026 | quiverquant.comQWhy Hyperliquid Strategies Inc.’s (PURR) Stock Is Up 12.26%May 28, 2026 | aaii.comAGoldman Sachs Sells XRP and SOL ETF, Pivots to Hyperliquid in Q1 2026May 22, 2026 | memeburn.comMHyperliquid token surges toward all-time high after spot ETF inflows hit record – 'Everything is down lately except HYPE,' says analystMay 22, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGNX, PURR, JBIO, and CVAC Company DescriptionsCureVac NASDAQ:CVAC$4.66 0.00 (0.00%) As of 07/13/2026CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Jade Biosciences NASDAQ:JBIO$21.34 +0.04 (+0.19%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$22.00 +0.66 (+3.09%) As of 07:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.MacroGenics NASDAQ:MGNX$4.29 -0.21 (-4.67%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$4.53 +0.24 (+5.50%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Hyperliquid Strategies NASDAQ:PURR$7.36 +0.20 (+2.79%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$7.54 +0.18 (+2.38%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
